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Abstract
Background—Candidate gene association studies for peripheral artery disease (PAD), including
subclinical disease assessed with the ankle-brachial index (ABI), have been limited by the modest
number of genes examined. We conducted a two stage meta-analysis of ~50,000 SNPs across
~2100 candidate genes to identify genetic variants for ABI.
Methods and results—We studied subjects of European ancestry from 8 studies (n = 21,547,
55% women, mean age 44–73 years) and African American ancestry from 5 studies (n = 7267,
60% women, mean age 41–73 years) involved in the candidate gene association resource (CARe)
consortium. In each ethnic group, additive genetic models were used (with each additional copy of
the minor allele corresponding to the given beta) to test each SNP for association with continuous
ABI (excluding ABI > 1.40) and PAD (defined as ABI < 0.90) using linear or logistic regression
with adjustment for known PAD risk factors and population stratification. We then conducted a
fixed-effects inverse-variance weighted meta-analyses considering a p < 2 × 10−6 to denote
statistical significance.
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Results—In the European ancestry discovery meta-analyses, rs2171209 in SYTL3 (β = −0.007,
p = 6.02 × 10−7) and rs290481 in TCF7L2 (β = −0.008, p = 7.01 × 10−7) were significantly
associated with ABI. None of the SNP associations for PAD were significant, though a SNP in
CYP2B6 (p = 4.99 × 10−5) was among the strongest associations. These 3 genes are linked to key
PAD risk factors (lipoprotein(a), type 2 diabetes, and smoking behavior, respectively). We sought
replication in 6 population-based and 3 clinical samples (n = 15,440) for rs290481 and rs2171209.
However, in the replication stage (rs2171209, p = 0.75; rs290481, p = 0.19) and in the combined
discovery and replication analysis the SNP–ABI associations were no longer significant
(rs2171209, p = 1.14 × 10−3; rs290481, p = 8.88 × 10−5). In African Americans, none of the SNP
associations for ABI or PAD achieved an experiment-wide level of significance.
Conclusions—Genetic determinants of ABI and PAD remain elusive. Follow-up of these
preliminary findings may uncover important biology given the known gene-risk factor
associations. New and more powerful approaches to PAD gene discovery are warranted.
Keywords
Ankle brachial index; Peripheral artery disease; Genetics; Candidate gene array; Meta-analysis;
Ethnicity
1. Introduction
Peripheral artery disease (PAD) is associated with an increased risk for incident
cardiovascular disease events and mortality [1,2]. In the reduction of atherothrombosis for
continued health (REACH) registry, almost two-thirds of the individuals with PAD had
concomitant clinically evident atherosclerotic disease in the cerebrovascular or coronary
artery disease (CAD) territories whereas only one-quarter of the individuals with coronary
disease had clinically evident atherosclerotic involvement of other arterial beds [3]. While
PAD and CAD share many common risk factors, cigarette smoking and type 2 diabetes are
stronger risk factors for PAD than for coronary artery disease [4]. The variable distribution
of the burden of atherosclerosis across vascular beds among subjects at risk suggests that
other factors exist, including possibly genetic factors, that may contribute to the predilection
of atherosclerosis to develop in a given anatomic location. Currently, little is known about
the genetic susceptibility to PAD but familial aggregation of PAD and heritability estimates
suggest a significant genetic contribution [5–10].
The ankle brachial index (ABI) is an easy and reliable diagnostic test used to detect
symptomatic as well as asymptomatic PAD [11]. A genome-wide linkage scan for ABI
identified several potential candidate genes under six linkage signals in pathways of
inflammation, coagulation, blood pressure regulation, and lipid metabolism [8]. A recent
large genome-wide association study (GWAS) meta-analysis of European descent
participants found variants in the 9p21 locus significantly associated with ABI [12].
However, there have been few candidate gene association studies for PAD, most of which
have been limited by small sample size, modest number of genes examined, and lack of
robust independent replication of initial findings [13]. We conducted a two stage large scale
candidate gene association study of the ~2100 candidate genes included in a cardiovascular
gene-centric 50K single nucleotide polymorphism (SNP) array [14] within the candidate
gene association resource (CARe) consortium that included 21,547 individuals of European
ancestry (1190 with ABI < 0.9) from eight cohorts and 7267 African American individuals
(594 with ABI < 0.90) from six cohorts. In the second stage of the investigation, we sought
to replicate our significant associations among individuals of European ancestry in 13,524
individuals from population-based cohort studies and 1916 individuals from clinically based
studies. We hypothesized that this approach would lead to the identification of novel genetic
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variants associated with ABI and PAD (as defined by an ABI < 0.90). Furthermore, we
hypothesized that some variants may influence both PAD risk factors and PAD itself, as has
been observed in genome-wide studies of lipids and coronary artery disease [15,16].
2. Methods
2.1. Discovery studies: CARe consortium and additional studies
The CARe consortium (http://public.nhlbi.nih.gov/GeneticsGenomics/home/care.aspx) was
funded by the National Heart Lung and Blood Institute (NHLBI) in 2006 to explore the
association of a custom cardiovascular gene centric SNP array [14] with a broad set of
cardiovascular, metabolic, and inflammatory phenotypes collected across nine longitudinal
cohort studies [17]. The following CARe consortium studies contributed data to the present
analysis (Tables 1A and 1B): atherosclerosis risk in communities study (ARIC, n = 9031
European Americans, n = 2853 African Americans), the Cleveland family study (CFS, n =
275 European Americans, n = 365 African Americans), the cardiovascular health study
(CHS, n = 3826 European Americans, n = 722 African Americans), the Framingham heart
study (FHS, n = 2701 European Americans), the Jackson heart study (JHS, n = 1734 African
Americans), and the multi-ethnic study of atherosclerosis (MESA, n = 2280 European
Americans, n = 1593 African Americans). The Amish study (n = 1008), the cooperative
research in the region of Augsburg (KORA F3, n = 1807), and the Penn diabetes heart study
(PDHS, n = 622) cohort all used the same cardiovascular gene centric SNP array and joined
the discovery stage analyses conducted in European Americans.
Description of each study is provided in the Supplementary Materials. For all studies, each
participant self-identified as either White (European, European American) or African
American and provided written informed consent. The Institutional Review Board at the
parent institution for each respective study approved the study protocols.
The characteristics of the discovery study samples at the time of ABI measurement are
presented in Tables 1A and 1B by ethnic group. More than half were women and the mean
age ranged from 44 years (CFS) to 73 years (CHS) in samples of European ancestry, and
from 41 years (CFS) to 73 years (CHS) in African Americans. The mean ABI was 1.10 and
the prevalence of PAD (ABI < 0.90) varied across studies, ranging from 4% to 12% in
European Americans and from 5% to 21% in African Americans. Risk factor burden
appeared greater in African Americans, as demonstrated by higher prevalence of
hypertension, type 2 diabetes, and obesity compared to European ancestry participants.
2.2. ABI phenotypes
The details of the ABI protocol for each study are provided in Supplementary Materials,
Supplementary Methods Table 1. For each leg, the systolic blood pressure at each ankle was
divided by the systolic blood pressure in the arm. In the ARIC study, ABI was measured in
only one leg and one arm chosen at random. The lower of the two ABIs calculated with each
leg was used for analyses with the exception of the Amish study which used the average of
an individual’s two ABIs in the analyses.
We defined two PAD phenotypes for genetic association analyses. First, we used the
continuous range of ABI ≤ 1.40. Next, we defined PAD as ABI < 0.90 and conducted a case
(ABI < 0.9)/control comparison (ABI ≥ 0.90 and < 1.40) analysis. Participants with an ABI
> 1.40 were excluded as these subjects likely had medial artery calcification and therefore
the artery would not be compressible to allow for determination of pressure in the artery.
Excluding participants with ABI did not truncate the distribution substantially, and ABI was
still normally distributed.
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Genotyping in the CARe cohorts and PDHS was conducted at the Broad Institute using the
ITMAT-Broad-CARe (IBC) Illumina iSELECT custom array [14]. The Old Order Amish
Study genotyping was also performed using the ITMAT IBC Illumina iSELECT custom
array. For KORA F3 (Discovery stage) genotyping with the same array was performed in
the Genome Analysis Centre, Helmholtz Zentrum München.
The IBC array was designed to capture genetic variation in loci known or postulated to be
associated with cardiovascular disease, metabolic disease and inflammatory diseases [14].
Specifically, a cosmopolitan tagging approach was used to capture genetic diversity across
~2100 candidate genes [14]. Loci were primarily chosen in three groups as follows: (1) 435
loci were chosen areas with a high probability of functional significance, (2) 1349 loci were
chosen as having involvement in phenotypes of interest (i.e. cardiovascular disease or
cardiovascular disease-related traits such as inflammation, hemostasis, obesity, diabetes) or
were well-established loci requiring a number of SNPs for coverage, and (3) 232 lower
priority loci were chosen, which also included larger genes [14]. Further details on the IBC
array can be found elsewhere [14]. Details of the genotyping and quality control procedures
are provided in Supplementary Methods Table 2.
2.4. Statistical analysis
For each study, residuals of ABI stratified by gender and race were created from linear
regression models and used as phenotypes in the association analysis; results of gender were
pooled but all analyses were stratified by race. The ABI residuals were adjusted for age,
clinic site for multi-site studies, principal components (participants of European ancestry) or
global European ancestry (African American participants), ever smoking, type 2 diabetes,
hypertension (>140/90 or use of anti-hypertensive medication), LDL cholesterol, HDL
cholesterol, and body mass index (BMI). In each ethnic group, SNPs were modeled
additively, and the association of each SNP with ABI was tested using linear regression. The
PDHS study did not use diabetes as a covariate as all subjects were diagnosed with type 2
diabetes. For CFS and FHS, linear mixed effects (LME) models were used to account for
familial correlations. Multivariable logistic regression was used to test for the association of
each SNP with PAD. For CFS and FHS, generalized estimating equations (GEE) were used
to account for familial correlations. The covariate adjustment for PAD was the same as used
for the ABI phenotype.
A fixed effects meta-analysis with inverse-variance weighting was then conducted in PLINK
V 1.0.6 [18] and Stata V 9.0 (College Station, TX) to combine the results for all studies. The
association of each additional copy of the minor allele with ABI was quantified by the
regression slope (β), its standard error [SE(β)] and the corresponding p-value. We calculated
a meta-analysis odds ratio (OR) for each of the most significant SNP associations for PAD.
The meta-analysis OR represents the increase/decrease in odds of PAD for each additional
copy of the minor allele of the SNP. We also tested for heterogeneity of study-specific
regression parameters using the Cochran’s Q statistic in Stata V9.0, and report the p-values
for heterogeneity. Associations were considered to be significant on an experiment-wide
level at a p-value ≤ 2 × 10−6 which was determined based on the estimate of the number of
independent tests [19]. SNPs with MAF < 0.01 were excluded.
A gene-based test of association using the meta-analyzed p-values at the discovery stage was
performed using the program Versatile Gene-Based Association Study (VEGAS) [20];http://
gump.qimr.edu.au/VEGAS/). The SNPs are matched to genes using the UCSC Genome
Browser hg18 assembly with the gene region defined by ±50 kb up-and downstream of the
gene. The test is based on the sum of chi-square-statistics and the linkage disequilibrium
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(LD) of these SNPs is taken into account according to the correlation structure in the
HapMap CEU samples. An empirical p-value is provided based on all SNPs, as well as
based on the SNPs within the top 20% with regard to their p-value. Since roughly 2100
genes are covered by the IBC chip, a p-value < 2.4 × 10−5 is considered significant.
2.5. Replication
Given that contemporary genetics consortia and results indicate that very large replication
samples are needed to successfully replicate SNPs, and that false positives are an ongoing
issue in studies such as these, we attempted to replicate only the two SNPs that met
experiment-wide significance for ABI in European Americans in an additional 13,524
individuals of European ancestry from six population-based studies (Copenhagen city heart
study, n = 5182; genetic study of aspirin responsiveness (GeneS-TAR), n = 618; KORA F3
(independent of KORA F3 participants in the discovery sample), n = 1440; KORA F4, n =
411; national health and nutrition examination survey (NHANES), n = 2358, and prevention
of renal and vascular end-stage disease (PREVEND), n = 3515) and 1916 individuals of
European ancestry from clinically based samples (cardiovascular disease in intermittent
claudication (CAVASIC), n = 434; genetic determinants of peripheral arterial disease
(GenePAD), n = 811; and Linz peripheral arterial disease (LIPAD), n = 671). GeneSTAR
provided in silico genotyping (genotyped participants with the same candidate gene chip
used in the discovery cohorts) while in the remaining studies genotyped the 2 SNPs de novo
using Taqman or Sequenom genotyping platforms. Description of the replication studies,
ABI protocol and calculation, and participant characteristics are provided in Supplementary
Methods, Supplementary Method Table 1 and Supplementary Results Table 1.
2.6. Power and sample size for discovery and replication stages
Participants of European ancestry—With a minor allele frequency (MAF) of 0.10,
additive SNP modeling, and experiment-wide significance level of 2 × 10−6, for each
additional copy of the risk allele, we have 80% power to detect a beta coefficient for ABI of
0.0092 and an OR for PAD of 1.45 in the discovery stage (n = 21,547). For European
ancestry individuals in the replication stage for ABI (n = 15,440) using the more stringent
significance level of 2 × 10−6 we have 80% power to detect a beta coefficient of 0.0106;
using a less stringent level (i.e. α = 0.025 based on carrying forward 2 SNPs for replication),
we have 80% power to detect a beta coefficient of 0.0058. In the discovery plus replication
stage for ABI (n = 36, 987), we have 80% power to detect a beta coefficient of 0.0065 using
2 × 10−6 as the type 1 error rate.
Participants of African-American ancestry—With a minor allele frequency (MAF) of
0.10, additive SNP modeling, and experiment-wide significance level of 2 × 10−6, for each
additional copy of the risk allele, we have 80% power to detect a beta coefficient for ABI of
0.0155 and an OR for PAD of 1.67 in the sample of 7267 individuals in the discovery stage.
No replication sample was available for this ethnicity.
3. Results
3.1. European ancestry studies: meta-analysis of ABI and PAD
In European ancestry discovery samples, two SNPs were significantly associated with ABI
(Table 2A, Figs. 1 and 2): each additional copy of the minor allele of rs2171209 in SYTL3
was associated with a 0.007 lower ABI (95% CI −0.010, 0.004, p = 6.02 × 10−7, p for
heterogeneity = 0.55) and each additional copy of the minor allele of rs290481 in TCF7L2
was associated with a 0.008 lower ABI (95% CI −0.011, −0.005, p = 7.01 × 10−7, p for
heterogeneity = 0.08). Rs290481 is located in intron 14 within the 3′ region of the TCF7L2
gene on chromosome 10 is distinct from a cluster of SNPs in the 5′ region of TCF7L2
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(represented by rs7903146), previously reported to be associated with type 2 diabetes in
genome-wide association studies (r2 = 0.001 between rs290481 and rs7903146) [21].
Among those of European ancestry, rs2171209 was not significantly associated with the
categorical PAD diagnosis made by the ABI threshold of 0.90 – each additional copy of the
minor allele was associated with just a 1.09-fold greater odds of PAD (95% CI: 0.97, 1.22, p
= 0.14); however, rs290481 was associated with PAD (OR = 1.20, 95% CI: 1.06, 1.35, p =
0.004), although this association did not meet the experiment-wide significance level. There
was no association between rs290481 and ABI (β = 0.001 95% CI: −0.006, 0.005, p = 0.80)
or rs2171209 and ABI (β =−0.002 95% CI −0.009, 0.004 p = 0.46) detected in African
Americans. One additional SNP was nominally associated with ABI in individuals of
European ancestry at p < 10−4 (Table 2A). The most significant SNP associations for ABI in
models minimally adjusted for age, sex, and study site only remained similar to the fully
adjusted models. When we removed all participants with type 2 diabetes from the analysis of
the CARe studies (ARIC, CFS, CHS, FHS and MESA), the beta coefficients were
essentially unchanged from those in Table 2A. Similarly, when we removed participants less
than 60 years of age from the analysis in the CARe studies, beta coefficients were
essentially unchanged from those in Table 2A.
Because rs290481 is located in a gene previously strongly associated with type 2 diabetes,
we conducted a test for interaction of this genotype with type 2 diabetes for ABI within the
CARe discovery cohorts (ARIC, CFS, CHS, FHS, MESA). The test for interaction was
performed on an additive scale using linear regression within each CARe cohort, and then
combining the results in the diabetes and no diabetes strata using fixed effect inverse-
variance weighting meta-analysis. The magnitude of the effect with ABI was greater in
diabetics (p for interaction 0.04, Supplementary Results Table 2, with each copy of the
minor allele in participants with diabetes conferring a lower level of ABI (n = 1896, β =
−0.03, p < 0.001) compared to participants without diabetes (n = 16,685, β = −0.007, p =
0.007).
The gene-based analysis using VEGAS at the discovery stage did not reveal any different
significantly associated genes with continuous ABI from our individual SNP analysis
(Supplementary Results Table 3). SYTL3 and TCF7L2 were among the most significant
genes for both analyses using all SNPs and the top 20% of SNPs (SYTL3: p(all SNPs) =
0.00216, p(top20% of SNPs) = 0.00007; TCF7L2: p(all SNPs) = 0.03589 p(top20% of
SNPs) = 0.00161).
In the replication stage, the association between ABI and rs2171209 in SYTL3 was not
significant in the population-based (β = −0.0004, n = 13,510, p = 0.73) and clinically based
replication samples (β = 0.001, n = 1890, p = 0.82) (Fig. 3). Consequently, in the combined
discovery plus replication meta-analysis the association was no longer significant (n =
36,947, β −0.003, p = 1.14 × 10−3) (Fig. 3). rs290481 in TCF7L2 also failed to replicate in
the population-based replication studies (β = −0.001, n = 13,505, p = 0.38) and in the
clinically based replication studies (β = 0.008, n = 1896, p = 0.20) (Fig. 4). In the combined
discovery and replication meta-analysis the association between rs290481 and ABI no
longer met experiment-wide significance (n = 36,855, β 0.004, p = 8.88 × 10−5) (Fig. 4).
None of the SNP associations in individuals of European ancestry achieved experiment-wide
significance for PAD (Table 2B). One of the most significant associations for PAD was in a
coding, non-synonymous SNP rs3745274 on chromosome 19 in CYP2B6 (OR 1.24, p =
4.99 × 10−5).
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3.2. African-Americans: meta-analysis of ABI and PAD
In African Americans none of the SNP associations with ABI and PAD were statistically
significant (Tables 3A and 3B). The strongest association for ABI was rs2243100 on
chromosome 17 in SLC25A11 (β 0.011 95% CI 0.006, 0.017, p = 5 × 10−5) and for PAD
was rs4987756 on chromosome 18 in BCL2 (OR 2.99, 95% CI 1.88, 4.76, p = 3.78 × 10−6).
4. Discussion
We conducted a large candidate gene association study of ~2100 cardiovascular candidate
genes for ABI and PAD in over 21,000 individuals of European ancestry and over 7000
African Americans. In individuals of European ancestry, a SNP in the TCF7L2 gene
(rs290481) and a SNP in the SYTL3 gene (rs2171209) were significantly associated in the
discovery stage with variation in ABI measurements and a suggestive association was
identified in a SNP in CYP2B6 for PAD. These findings are intriguing as the genes are
linked to key PAD risk factors. TCF7L2 is the strongest genetic risk factor for susceptibility
to type 2 diabetes [22–25] and CYP2B6 affects smoking behavior [26] and thus may be
important in tobacco-related diseases such as PAD. However, we were unable to replicate
the SNP–ABI associations in additional samples from population-based studies or clinically
based samples. Furthermore, the associations were not detected in African Americans. We
did not observe any significant associations for ABI or PAD in African Americans, possibly
due to the relatively small sample size limiting our power to detect associations.
4.1. In the context of the current literature
Genetic factors leading to susceptibility to PAD remain largely unknown but are likely to be
attributed to variants in many genes, each with small effects [13] or possibly from rare
variants (minor allele frequency < 1%) with larger effects. While many of these variants
may lead to risk for PAD through effects on established risk factors or shared effects with
CAD and other atherosclerotic diseases [27], other variants may uniquely influence
development of arterial disease in the lower extremities. Although our findings after the
discovery stage did not bear out in the replication samples, the two genes are interesting
candidates for ABI in light of the current literature and deserve some discussion. Genome-
wide association studies of individuals of European ancestry have consistently reported an
association between genetic variants of TCF7L2 and type 2 diabetes that has been confirmed
in Japanese and African American samples [19,22–24,28–30]. However, our SNP in
TCF7L2, rs290481 was not significantly associated with type 2 diabetes in large scale
association analysis [21]. The replicated index SNP in TCF7L2 associated with type 2
diabetes is rs7902146. Further, rs290481 is not in linkage disequilibrium with rs7902146 (r2
= 0.001) [21]. TCF7L2 encodes a high mobility group (HMG) box-containing transcription
factor that is involved in the Wnt signaling pathway [31] and is associated with impaired
beta cell function, impaired insulin secretion and increased hepatic glucose production.
Therefore, the TCF7L2 association in our discovery cohorts that presented even after
adjusting for type 2 diabetes might deserve further attention in functional studies to elucidate
its role in atherosclerosis.
The association between SYTL3 and ABI may be mediated by lipoprotein(a) (Lp(a)). A
genome-wide association study in a small founder population of 386 Hutterites identified an
association between the extended LPA gene region on chromosome 6q26–q27 including
SYTL3 SNPs with Lp(a) levels[32]. Genetic variation within the LPA gene region including
a very common copy number variation and other genetic variants explain up to 90% of Lp(a)
concentrations[33]. Since Lp(a) concentrations and genetic variants within the LPA region
are a strong risk factor for cardiovascular disease[34], it might well be that a SNP in the
SYTL3 gene reflects a signal from LPA. Polymorphisms within the LPA gene region were
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associated with PAD in a past study [35]. Lp(a) may be an independent risk factor for PAD
[36] but results are conflicting [37,38].
4.2. Strengths and limitations
To our knowledge this study is the largest candidate gene association study concerning ABI
conducted in both individuals of European ancestry and African Americans and includes the
most extensive number of candidate genes investigated. In the CARe consortium, imputed
GWAS data is available on the African-American participants; however, given our relatively
modest African-American sample size, we chose to perform analysis of the IBC chip first.
We have also chosen the IBC chip because it was specifically designed as a large scale
cardiovascular-centric candidate gene array, and the genetic variants on the chip were
informed by GWAS for vascular and inflammatory diseases as well as expression QTLs for
atherosclerosis.
Several limitations of our candidate gene meta-analysis merit comment: (i) The ankle-
brachial blood pressure measurement protocols used in the studies were heterogeneous.
Hence, phenotype heterogeneity may have impacted our ability to detect associations. (ii)
The ARIC study contributed over 40% of the European ancestry sample and measured ABI
in only one leg which may have led to phenotype misclassification most problematic for the
PAD phenotype. The mean ABI did differ significantly between European Americans in
ARIC and European Americans from the other CARe cohorts (all p < 0.05) with mean ± SD
of the ARIC ABI 1.12 ± 0.13, CHS ABI 1.06 ± 0.15, CFS ABI 1.08 ± 0.10, FHS ABI 1.13 ±
0.12, and MESA ABI 1.11 ± 0.12. However, a sensitivity analysis excluding the ARIC
samples showed parameter estimates of similar size. (iii) Not all studies had information on
lower extremity revascularization, which may also have contributed to PAD
misclassification. In general, these misclassifications should cause bias toward the null. (iv)
Control selection bias could have affected our PAD results in some way, although given that
all of our studies except one (the PDHS) contributing to the PAD analysis were prospective
cohort studies where knowledge of PAD would not affect exposure (i.e. genotype status) and
the genotype precedes prevalent PAD, this is of lesser concern. For ABI analyses, we also
analyzed our clinical replication samples separately by case-control status to avoid
additional bias or heterogeneity. (v) Although we adjusted for population stratification using
principal components in the European ancestry analysis and global ancestry in the African-
American analysis, residual confounding could still be present. (vi) Our sample of African
Americans was modest in size and likely limited our power to detect associations. For
example, given the sample size of African-Americans we included and a risk allele
frequency of 0.10, we only had 80% power to detect an increment in ABI of approximately
0.02 or greater per each copy of the risk allele. The observed effect size of the experiment-
wide significant SNPs in European ancestry participants was much smaller than this value.
According to our calculations in the methods section, for the European ancestry analyses, we
can detect modest differences in ABI (similar to the ones we observed in this study), but are
likely underpowered for PAD.
Some of the mentioned limitations might have contributed to the observation that the most
important findings from the discovery phase could not be confirmed in the replication phase.
However, it is unlikely that this fully explains the differences between the two study stages
which necessitate additional large study samples.
5. Conclusions
The search for genes influencing ABI and PAD remains challenging. Although we cannot
claim new findings in our study, two associations at the discovery stage for ABI (SYTL3,
TCF7L2) may deserve further attention in other populations and functional studies. Further
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study of the genes identified in this study for ABI (SYTL3, TCF7L2) and PAD (CYP2B6) is
warranted in other populations as further investigation of the function of these loci may
uncover important biological insights into the pathogenesis of PAD. Identification of main
effects may have been difficult in our study due to the presence of interactions and
heterogeneity across participating studies. New and more powerful approaches to PAD gene
discovery are sorely needed.
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This plot shows the p-values for rs2171209, as well as for SNPs in the region of rs2171209,
with ABI in a meta-analysis of the discovery studies. The x-axis shows chromosomal
location in Mb (chromosome 10), as well as genes residing in this region. The y-axis on the
left displays the −log 10(p-value) for each SNP, and the y-axis on the right shows the
recombination rate in this region. The top SNP, rs2171209 is represented as a purple
diamond, while supporting SNPs and other SNPs in the area are color-coded by linkage
disequilibrium with rs2171209 (see r2 linkage disequilibrium legend on the plot). (For
interpretation of the references to color in this figure legend, the reader is referred to the web
version of the article.)
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This plot shows the p-values for rs290481, as well as for SNPs in the region of rs290481,
with ABI in a meta-analysis of the discovery studies. The x-axis shows chromosomal
location in Mb (chromosome 10), as well as genes residing in this region. The y-axis on the
left displays the −log 10(p-value) for each SNP, and the y-axis on the right shows the
recombination rate in this region. The top SNP, rs290481 is represented as a purple
diamond, while supporting SNPs and other SNPs in the area are color-coded by linkage
disequilibrium with rs290481 (see r2 linkage disequilibrium legend on the plot). (For
interpretation of the references to color in this figure legend, the reader is referred to the web
version of the article.)
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This plot shows the association of rs2171209 with ABI for each of the discovery and
replication studies, and then results with these studies combined by meta-analysis. The x-
axis contains beta coefficients for the association of rs2171209 with ABI in the discovery
and replication studies, and the y-axis shows studies or groups of studies. Circles represent
the beta coefficient (except for overall replication and discovery + replication meta-analysis
results, where beta coefficients are designated by a diamond), and error bars are 95%
confidence intervals. p-Values for heterogeneity are by Cochran’s Q. Study abbreviations
are as follows: ARIC = atherosclerosis risk in communities, CFS = Cleveland family study,
CHS = cardiovascular health study, FHS = Framingham heart study, MESA = multi-ethnic
study of atherosclerosis, KORA F3 and KORA F4 = cooperative research in the region of
Augsburg, PDHS = Penn diabetes heart study, GeneSTAR = genetic study of aspirin
responsiveness, PREVEND = prevention of renal and vascular end-stage disease,
Copenhagen = Copenhagen city heart study, NHANES = national health and nutrition
examination survey, LIPAD = Linz peripheral arterial disease, CAVASIC = cardiovascular
disease in intermittent claudication, and GenePAD = genetic determinants of peripheral
arterial disease.
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This plot shows the association of rs290481 with ABI for each of the discovery and
replication studies, and then results with these studies combined by meta-analysis. The x-
axis contains beta coefficients for the association of rs290481 with ABI in the discovery and
replication studies, and the y-axis shows studies or groups of studies. Circles represent the
beta coefficient (except for overall replication and discovery + replication meta-analysis
results, where beta coefficients are designated by a diamond), and error bars are 95%
confidence intervals. p-Values for heterogeneity are by Cochran’s Q. Study abbreviations
are as follows: ARIC = atherosclerosis risk in communities, CFS = Cleveland family study,
CHS = cardiovascular health study, FHS = Framingham heart study, MESA = multi-ethnic
study of atherosclerosis, KORA F3 and KORA F4 = cooperative research in the region of
Augsburg, PDHS = Penn diabetes heart study, GeneSTAR = genetic study of aspirin
responsiveness, PREVEND = prevention of renal and vascular end-stage disease,
Copenhagen = Copenhagen city heart study, NHANES = national health and nutrition
examination survey, LIPAD = Linz peripheral arterial disease, CAVASIC = cardiovascular
disease in intermittent claudication, and GenePAD = genetic determinants of peripheral
arterial disease.
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Table 1A
Characteristics of discovery samples at the time of ankle brachial index (ABI) measurement. European and
European Americans.a
Characteristic mean


















Age (years) 5±6 44±19 73±6 61±9 63±10 44±14 62±11 59±9
Women (%) 4871 (54%) 145 (53%) 2152 (56%) 1453 (54%) 1196 (52%) 484 (48%) 965 (53%) 429 (69%)
ABI (mean) 1.13±0.13 1.08±0.10 1.06±0.16 1.13±0.12 1.11±0.12 1.10±0.10 1.11±0.13 1.12±0.14
PAD (ABI < 0.9) (%) 334 (4%) 12 (4%) 453 (12%) 100 (4%) 105 (5%) 36 (3.6%) 92 (5%) 40 (6.5%)
Hypertension (%) 2410 (27%) 85 (31%) 2136 (56%) 629 (23%) 882 (39%) 125 (12%) 1046 (58%) 361 (58%)
Diabetes (%) 785 (9%) 34 (12%) 547 (14%) 288 (11%) 141 (6%) 6 (0.6%) 168 (9%) 622 (100%)
Body mass index (kg/
m2) 27±5 32±9 26±4 28±5 28±5 27±5 28±5 33±6
Ever smoker (%) 5387 (60%) 120 (44%) 2076 (54%) 1595 (59%) 1274 (56%) 239 (24%) 929 (51%) 361 (58%)
Total cholesterol (mg/dL) 215±41 192±42 211±39 200±36 196±36 209±47 222±40 177±38
LDL cholesterol (mg/dL) 137±38 102±30 130±35 119±33 117±30 139±4 130±33 99±30
HDL cholesterol (mg/dL) 51±17 44±12 54±16 54±17 52±16 56±15 59±17 46±13
Triglyceride (mg/dL) 137±93 139±101 144±79 137±89 134±92 69±41 171±133 155±88
Lipid lowering meds (%) 297 (3%) 40 (15%) 73 (2%) 559 (21%) 414 (18%) 32 (2%) 247 (14%) 386 (62%)
Claudication (%) 70 (0.8%) 3 (1%) 79 (2%) 45 (2%) 9 (0.4%) N/Ac 67 (3.7%) 0 (0%)
Prevalent CVD (%) 0 (0%) 14 (5%) 879 (23%) 110 (4%) 0 (0%) 28 (2.9%) 227 (13%) 0 (0%)
a
ARIC = atherosclerosis risk in communities, CFS = Cleveland family study, CHS = cardiovascular health study, FHS = Framingham heart study,
MESA = multi-ethnic study of atherosclerosis, KORA F3 = cooperative research in the region of Augsburg, PDHS = Penn diabetes heart study.
b
Includes both original cohort and offspring cohort.
c
N/A = not measured or assessed in the study.
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Table 1B
Characteristics of discovery samples at the time of ankle brachial index (ABI) measurement. African
Americans.a
Characteristic mean (SD) or n (%) ARIC n = 2853 CFS n = 365 CHS n = 722 JHS n = 1734 MESA n = 1593
Age (years) 53±6 41±19 73±6 50±12 62±10
Women (%) 1798 (63%) 208 (57%) 454 (63%) 1051 (61%) 867 (54%)
ABI (mean) 1.1±0.1 1.0±0.1 1.0±0.2 1.1±0.1 1.1±0.1
PAD (ABI < 0.9) (%) 148 (5%) 45 (12%) 153 (21%) 105 (6%) 143 (9%)
Hypertension (%) 1578 (55%) 155 (42%) 520 (72%) 970 (56%) 959 (60%)
Diabetes (%) 543 (19%) 72 (20%) 170 (24%) 251 (14%) 281 (18%)
Body mass index (kg/m2) 30±6 33±9 28±6 32±7 30±6
Ever smoker (%) 1500 (53%) 175 (48%) 367 (51%) 544 (31%) 860 (54%)
Total cholesterol (mg/dL) 215±45 183±43 209±39 197±39 189±36
LDL cholesterol (mg/dL) 138±43 97±34 128±36 126±36 116±33
HDL cholesterol (mg/dL) 55±18 44±13 58±16 51±14 52±15
Triglyceride (mg/dL) 113±74 103±63 116±63 106±89 105±71
Lipid lowering meds (%) 39 (1%) 50 (14%) 32 (4%) 154 (9%) 252 (16%)
Claudication (%) 18 (0.6%) 3 (0.8%) 11 (2%) 534 (30%) 10 (0.6%)
Prevalent CVD (%) 0 (0%) 11 (3%) 191 (26%) 98 (6%) 0 (0%)
a
ARIC = atherosclerosis risk in communities, CFS = Cleveland family study, CHS = cardiovascular heart study, JHS = Jackson heart study, MESA
= multi-ethnic study of atherosclerosis.
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